BioLineRx Stock Scheduled to Reverse Split on Thursday, January 30th (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX) shares are set to reverse split on the morning of Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 29th.

BioLineRx Price Performance

Shares of NASDAQ BLRX opened at $0.11 on Wednesday. BioLineRx has a fifty-two week low of $0.08 and a fifty-two week high of $1.44. The stock has a market cap of $8.39 million, a price-to-earnings ratio of -0.48 and a beta of 1.46. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The firm’s 50-day simple moving average is $0.25 and its 200 day simple moving average is $0.48.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. As a group, research analysts anticipate that BioLineRx will post -0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HC Wainwright dropped their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th. StockNews.com assumed coverage on shares of BioLineRx in a research report on Sunday. They set a “hold” rating on the stock.

Institutional Investors Weigh In On BioLineRx

Hedge funds have recently modified their holdings of the stock. PVG Asset Management Corp bought a new stake in shares of BioLineRx in the 2nd quarter worth approximately $70,000. Atria Investments Inc raised its holdings in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC bought a new stake in shares of BioLineRx in the 2nd quarter worth approximately $462,000. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.